Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced full year 2024 ...
Precigen (PGEN) reported better-than-expected first-quarter earnings and is making strides toward commercializing its lead asset, PRGN-2012, for recurrent respiratory papillomatosis. The FDA has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback